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Opioids and their receptors have received remarkable attention because they have the
ability to alter immune function, which affects disease progression. In vitro and in vivo
findings as well as observations in humans indicate that opioids and their receptors
positively or negatively affect viral replication and virus-mediated pathology. The present
study reviews recent insights in the role of opioids and their receptors in viral infections
and discusses possible therapeutic opportunities. This review supports the emerging
concept that opioids and their receptors have both favorable and unfavorable effects on
viral disease, depending on the type of virus. Targeting of the opioid system is a potential
option for developing effective therapies; however caution is required in relation to the
beneficial functions of opioid systems.
Keywords: opioids, opioid receptors, immunomodulation, viral infections, therapies, immune responses, opioid
signaling, anti-inflammation
OPIOIDS AND THEIR RECEPTORS
Opioids are a group of endogenous and exogenous/synthetic compounds that function through
activation of opioid receptors (McNally and Akil, 2002). Opioid receptors have been isolated,
cloned, and classified asµ-opioid receptors (MORs), δ-opioid receptors (DORs), κ-opioid receptors
(KORs), and opioid-like receptors (ORL), and are encoded by OPRM1, OPRD1, OPRK1, and OLR
genes, respectively (Stevens, 2009). The MOR (µ1, µ2, µ3), DOR (δ1, δ2), and KOR (κ1, κ2, κ3)
opioid receptor genes have been cloned (Herz, 1998). Opioid receptors are mainly distributed in
the central and peripheral nervous system, as well as in non-neuronal cells in the lung, spleen, liver,
intestine, adenoid, and kidney (Wittert et al., 1996).
The receptors are transmembrane G protein-coupled receptors (GPCRs) with an affinity
for endogenous opioid peptides and include β-endorphin, encephalin, met-enkephalin,
nociceptin, and exogenous natural and synthetic opioid agents (e.g., morphine, heroin;
Stein, 2016). A high degree of structural similarity (50–70%) has been observed in
the transmembrane domains 2, 3, and 7 and the first and second intracellular loops.
Abbreviations:MORs, µ-opioid receptors; DORs, δ-opioid receptors; KORs, κ-opioid receptors; GPCRs, G-protein-coupled
receptors; MAPK, mitogen-activated protein kinases; IP3, inositol-1,4,5-triphosphate; CCR, C-C chemokine receptor; CXCR,
C-X-C chemokine receptor; CXCL, C-X-C motif ligand; CCL, C-C motif ligand; HIV, human immunodeficiency virus;
Th, T-helper; CNS, central nervous system; miRNAs, microRNA; 3′-UTR, 3′-untranslatet region; ROS, reactive oxygen
species; NF-κB, nuclear factor-kappa B; gp, glycoprotein; Tat, transactivator of transcription; TNF-α, tumor necrosis factor-α;
IL, interleukin; HCV, hepatitis C virus; IFN, interferon; IRF, interferon regulatory factor; SOCS-3, suppressor of cytokine
signaling 3; PIAS-3, protein inhibitor of activated STAT3; NO, nitric oxide; BALF, bronchoalveolar lavage fluid; RSV,
respiratory syncytial virus; HSV, herpes simplex virus; BBB, blood-brain barrier.
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The extracellular domain diverges, which explains differences in
ligand selectivity between opioid receptors (McNally and Akil,
2002). Following activation of the opioid receptors, adenylyl
cyclase is inhibited, which activates K+ channels and diminishes
the conductance of voltage-sensitive Ca2+ channels (Stein, 2016).
Opioid receptors also activate mitogen-activated protein kinases
(MAPK) and phospholipase C-mediated signaling, leading to the
formation of IP3 and diacyl glycerol (Childers, 1991). All these
effects lead to activation or inhibition of several downstream
signals that contribute to the intrinsic effects of opioids (Stein,
2016).
OPIOIDS AND IMMUNE FUNCTION
Opioids and their derivatives are the oldest and most effective
drugs for treatment of pain (Lewis et al., 1987). They are
also one of the most popular recreational drugs and account
for 27 million users worldwide (UNODC, 2015). Opioid-
mediated analgesia occurs through modulation of ascending
and descending pain pathways (Kapitzke et al., 2005). The
immunomodulatory and anti-inflammatory properties of opioids
have also been well documented (Bidlack, 2000). Opioid
receptors are abundantly expressed on various immune cells (e.g.,
lymphocytes, macrophages, neutrophils, and monocytes) and it
has been shown that immune function is influenced by these
receptors (Figure 1; McCarthy et al., 2001; Odunayo et al., 2010).
It has been shown that immune cells contain opioid peptides such
as β-endorphin, metenkefalin, and dynorphin A, which have been
proposed to alleviate inflammatory hyperalgesia (Kapitzke et al.,
2005).
Numerous immune factors and immune responses are
significantly dampened following opioid exposure in drug
users, healthy human subjects, and animal models (Rogers and
Peterson, 2003; Sacerdote, 2006). These dampened immune
functions include suppressed cytokine/chemokine production
(Finley M. et al., 2008), cytokine/chemokine receptors expression
(Finley M. J. et al., 2008), antibody production (Taub et al.,
1991), lymphocyte proliferation (McCarthy and Rogers, 2001),
NK cell activity (Shavit et al., 1984), neutrophils function
(Simpkins et al., 1986), and macrophage phagocytic activity
(Rojavin et al., 1993). The activation of opioid receptors also
induces apoptosis in immune cells (Singhal et al., 1998); thus,
endogenous/exogenous opioids, opioid receptors, and opioid
signaling pathways together form a system (opioid system) which
modulates immune function (Salimi et al., 2013).
Opioid receptors and chemokine receptors and their ligands
are widely expressed in brain tissue and immune cells (McCarthy
et al., 2001). Multiple lines of evidence have shown that
interaction between opioids and chemokine receptors regulate
immune responses (Steele et al., 2002). Potential mechanisms for
this interaction include heterologous desensitization (also known
as cross-desensitization), changes in receptor expression, opioid
and chemokine receptor dimerization or heteromerization, and
regulation by the ferritin heavy chain (Rogers et al., 2000; Nash
and Meucci, 2014). Activation of GPCRs such as opioids on the
surface of immune cells often inhibits chemokine receptors by
heterologous desensitization. The inhibitory crosstalk between
opioids and chemokine receptors is believed to be a major
element in regulation of the function of these receptors (Ali
et al., 1999; Rogers et al., 2000). Several forms of desensitization
occur between opioid and chemokine receptors. MOR and DOR
are able to induce heterologous desensitization of CCR1, CCR2,
CCR5, CXCR1, and CXCR2 (Grimm et al., 1998). The CCR5
chemokine receptor can form heterodimers with the opioid
receptors MOR, DOR, and KOR (Steele et al., 2002; Szabo et al.,
2003; Chen et al., 2004). KOR is able to cross-desensitize CXCR4
(Finley M. J. et al., 2008) and ORL1 induces desensitization of
CXCR4 (Kaminsky and Rogers, 2011). Simultaneous stimulation
of CXCR4 and DOR-expressing cells by their respective ligands,
CXCL12 and DPDPE, does not trigger receptor function (Pello
et al., 2008). Opioid and CCR5/CXCR4 interaction potentially
contribute to HIV-associated neurocognitive disorders (Steele
et al., 2003).
Importantly, besides immunomodulatory and anti-
inflammatory activity, the opioid system could modulate
T-helper (Th) cytokine patterns (Sacerdote et al., 1998). Opioid
receptor antagonists stimulate cellular immune responses and
shifts immune responses to a Th1 pattern (Sacerdote et al., 2000;
Jazani et al., 2011; Khorshidvand et al., 2016). This ability to
induce and shift immune responses toward a Th1 pattern makes
opioid receptors antagonists as a new adjuvant candidate in the
induction of cellular immunity which could increase protection
against intracellular parasites (Khorshidvand et al., 2016). These
studies support the administration of opioid receptor blockers
such as naloxone and/or naltrexone as a vaccine adjuvant to
increase vaccine efficacy by enhancing cellular immunity (Jamali
et al., 2009; Jazani et al., 2010, 2011; Hajipirloo et al., 2014;
Shahabi et al., 2014; Khorshidvand et al., 2016). Taken together,
the inhibition of anti-inflammatory and immunomodulatory
activity of opioid signaling by opioid receptors antagonists
explains the mechanisms by which opioid antagonists trigger
vaccine-induced immunity (Khorshidvand et al., 2016).
Although many advances have been made in understanding the
effects of opioids system on immune regulation, it is necessary to
understand the real clinical relevance of this system (Ninkovic
and Roy, 2013).
OPIOIDS AND VIRAL INFECTION
Although intensive research has rapidly advanced knowledge
about the effect of the opioid system on immune function,
little is known about the role of this system in the initiation
and development of infection (Risdahl et al., 1998). Through
activation of opioid receptors, opioid systems effect diverse
biological functions, including both innate and adoptive immune
responses which can affect susceptibility to pathogens (Wang
et al., 2008). It is well documented that opioid abusers have
a higher prevalence of opportunistic infections, which may be
directly associated with impaired immune function (Roy et al.,
2011). Studies in healthy non-addicted individuals has revealed
that opioid treatment in obstetrics results in reactivation of latent
viruses, which can be directly explained by a dampened antiviral
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FIGURE 1 | Opioid systems effects on immune responses. Opioid receptors are abundantly expressed on various immune cells and immune function is
influenced by these receptors activation/inhibition. Numerous immune factors and immune responses are significantly dampened following opioid receptors activation.
Opioid and chemokine receptors interaction on the immune cells surface regulates immune responses; Activation of opioid receptors by their ligands desensitizes
chemokine receptors and also activation of chemokine receptor by its ligand desensitizes opioid receptor. Importantly, opioid receptors antagonists stimulates cellular
immune responses and shifts immune responses to a Th1 pattern.
immune function (Crone et al., 1988). A previous study by
the authors indicates that endogenous opioids can control viral
infection and could be useful for therapeutic applications (Salimi
et al., 2013).
Given the breadth of opioid-mediated signaling and immune
regulation in mammals, the role of the opioid system has
recently been highlighted in viral infections. The effects of
opioids and their receptors have been studied for several viral
infections (Table 1). Opioid systems affect viral replication
and pathogenesis in several ways (Figure 2). Interestingly,
opioids have either a beneficial or deleterious effect on the
pathogenesis of viruses directly through central nervous system
(CNS) by their intrinsic immunomodulatory actions (Hu et al.,
2011). Depending on the virus type, activation of opioid
receptors in immune and immune-associated cells directly or
indirectly enhances (Wang C.-Q. et al., 2005) or suppresses
viral pathogenesis by modulating host immune responses
(Coussons-Read et al., 1999; Salimi et al., 2013). Findings on
the ability of opioids to modulate epigenetic mechanisms, in
particular microRNAs (miRNAs) expression, shed new light on
possible mechanisms underlying the effect of opioids on viral
infection (Purohit et al., 2012; Pilakka-Kanthikeel and Nair,
2015). Furthermore, opioid interaction with viral receptors, viral
proteins, and viral promoters effect viral replication during the
course of an infection (Sundar et al., 1996; Steele et al., 2003;
Chang and Connaghan, 2012).
The present study summarizes and discusses the effect of the
opioid system on human viral infections, which are amongst the
most important human pathogens. It is proposed that opioid
system activity increases during viral infection and is involved
in viral pathogenesis. Understanding the role of opioid system
in viral infection is of importance for understanding disease
pathogenesis and could lead to novel therapeutic approaches for
viral infections.
Human Immunodeficiency Virus
Human immunodeficiency virus (HIV) causes acquired
immunodeficiency syndrome (AIDS), a serious cause of
death in humans of all ages (Maartens et al., 2014). Many
HIV-infected subjects abuse morphine, heroin, or other opioid-
related substances (Wang and Ho, 2011). Nearly half of those
problematic drug users inject drugs and an estimated 1.65million
of IV drug users were living with HIV in 2013 (UNODC, 2015).
Opioids have been suggested as promoting the pathogenesis of
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TABLE 1 | Opioid system effects on viral infections.
Viral infection Effects References
HIV
Opioids impair the anti-HIV activity of immune system Wang X. et al., 2005
MORs activation up-regulates the CCR5 and CXCR4 expression Steele et al., 2003
Opioids induce the pro-inflammatory mediators expression El-Hage et al., 2006
Opioid system disrupts the gut homeostasis Meng et al., 2015
Opioids inhibit the anti-HIV miRNAs expression Wang et al., 2011
Opioid system reactivate the HIV latently infection Prottengeier et al., 2014
Opioids induce the cytokine production and HIV promoter activation Sundar et al., 1996
Morphine alters the β-chemokines and CCR5 receptor expression Li et al., 2003a
Morphine limits the ability of neurons to recover from injury Masvekar et al., 2014
Morphine promotes the growth of HIV in human PBMC Peterson et al., 1990
Morphine exacerbates the neuropathogenesis process of HIV-1 gp 120 Mahajan et al., 2005
Morphine increases production of reactive free radical & oxidative stress Turchan-Cholewo et al., 2009
KORs activation suppresses HIV-1 expression in infected microglial Chao et al., 1996
KORs activation suppresses HIV-1 expression in human brain cells Chao et al., 1998
KORs activation inhibits HIV-1 expression in infected CD4 cells Peterson et al., 2001
KORs activation reduces HIV-1 entry Lokensgard et al., 2002
DORs activation in T cells reduces the expression of HIV-1 Sharp et al., 1998
DORs activation attenuates Tat-induced intracellular oxidative stress Wallace et al., 2006
MORs activation reduces HIV-1 replication in TF-1 cells Strazza et al., 2014
Opioids suppress IL-16-induced signaling pathways Chao et al., 1995
HCV
Opioid dependence therapy associates with lower incidence of HCV Tsui et al., 2014
Morphine compromises anti-HCV effect of recombinant IFN-α Li et al., 2003b
Morphine inhibits intracellular IFN-α expression Li et al., 2007
Morphine withdrawal inhibits expression of endogenous IFN-α Wang C.-Q. et al., 2005
Opioids impair CD56+ T cell-mediated innate immune function Ye et al., 2010
Morphine induces hepatic pro-inflammatory cytokine and free radicals El-Hage et al., 2011
Opioid system synergize the alcohol acceleration of HCV expression Zhang et al., 2003
β-endorphins down-modulates T cell anti-bacterial response Amati et al., 2001
Met-enkephalin enhances replication of HCV and interferes with interferon Bergasa and Boyella, 2008
Met-enkephalin as a marker in hepatocellular damage in chronic HCV Ciesla et al., 2006
Influenza
Morphine impairs the inflammatory response to influenza in the lungs Hu et al., 2011
Morphine treated rates slowly clear virus from their lungs Coussons-Read et al., 1998
Opioid system modulate NK cell cytotoxicity during influenza infection Tseng et al., 2005
Opioids could increase risk of pneumonia after influenza as a consequent of immune suppression Dublin et al., 2011
Exposure to methadone significantly increased H1N1 viral replication Chen et al., 2015
RSV The A118G single nucleotide polymorphism rs1799971 associated with RSV disease severity Salimi et al., 2013
Opioid system control RSV replication in the lung and consequently control virus immunopathogenesis Salimi et al., 2013
HSV
Morphine alters innate immune responses against HSV-1 Sheridan and Moynihan, 2005
Morphine diminishes protective innate immune defense against HSV-1 Jamali et al., 2007a
Morphine reduced CTL responses, lymphocyte proliferation, and IFN-γ Mojadadi et al., 2009
Withdrawal from morphine reduces protective immunity against HSV-1 Jamali et al., 2012
Endogenous opioids could suppress protective immunity against HSV-1 Jamali et al., 2007b
Morphine treatment reduces HSV-1 mortality in infected mice Alonzo and Carr, 1999
Morphine treatment reduces HSV-1 pathogenesis in infected mice Weeks et al., 2001
High incidence of HSV in patients given epidural morphine Gieraerts et al., 1987
Epidural morphine reactivates oral herpes in the obstetric population Crone et al., 1990
Morphine potentiates development of encephalitis in HSV-1 infected mice Lioy et al., 2006
Attenuated hippocampal dynorphin causes seizures in HSV-1 infected rats Solbrig et al., 2006
MORs activation by loperamide suppress mechanical allodynia in mice with herpetic pain Sasaki et al., 2007
MORs activation by morphine suppress mechanical allodynia in mice with herpetic pain Sasaki et al., 2008
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FIGURE 2 | Opioid systems effects on viral replication and pathogenesis. Opioids may positively or negatively affect the pathogenesis of viruses directly
through the central nervous system (Hu et al., 2011). Opioid receptors activation in immune and immune-associated cells directly or indirectly affect viral pathogenesis
via modulating host immune responses (Salimi et al., 2013). Modulation of epigenetic mechanisms such as miRNAs expression affect viral infection (Purohit et al.,
2012). Furthermore, interaction with several viral key factors such as viral receptors, viral proteins, and viral promoters may influence viral replication and
virus-medicated pathology (Sundar et al., 1996; Steele et al., 2003; Chang and Connaghan, 2012).
HIV in the CNS and exacerbating neurodegenerative diseases
caused by chronic HIV (Hauser et al., 2005). In addition,
HIV-infected opioid abusers are at higher risk of developing
HIV dementia (Turchan-Cholewo et al., 2008). Importantly,
accumulating evidence from in vitro and in vivo studies
indicates that the opioid system can act as a cofactor in the
immunopathogenesis of HIV, as they have the potential to
impair host immune response and enhance microbial infections
(Rouveix, 1992). Several mechanisms have been proposed for the
peripheral and neurotoxic effects of opioids in HIV infection,
viral replication, and disease progression (Figure 3).
The effect of opioids on the immune system plays an
essential role in HIV peripheral and CNS pathogenesis. Opioid
administration impairs the anti-HIV activity of the immune
system which enhances HIV pathogenesis (Wang X. et al., 2005).
Activation of opioid receptors, especially MOR, up-regulates
expression of the chemokine receptors CCR5 and CXCR4,
two major HIV-1 entry co-receptors, which promotes HIV-
1 replication (Steele et al., 2003). Opioids induce expression
of several pro-inflammatory mediators such as tumor necrosis
factor-α (TNF-α), interleukin (IL)-6, and CCL5 and accelerates
HIV neuropathogenesis (El-Hage et al., 2006). Opioids have been
shown to disrupt gut homeostasis by modulating gastrointestinal
motility and suppressing intestinal immune functions elevating
gut bacterial translocation, which activates the immune system
and accelerates disease progression during HIV infection (Meng
et al., 2015). Endogenous opioids, as do exogenous opioids, can
potentiate HIV-1 replication by inducing cytokine production
and stimulation of HIV promoter (Sundar et al., 1996).
Morphine is a widely-used opioid that accelerates HIV
peripheral pathogenesis in several ways. Morphine treatment
enhances susceptibility of neonatal monocyte-derived
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FIGURE 3 | Opioid systems effects on HIV replication and pathogenesis. Opioid system accelerate HIV pathogenesis and enhance susceptibility to HIV via
several mechanisms. Opioid system impair the anti-HIV activity of immune system (Wang X. et al., 2005), inhibit the expression of anti-HIV miRNAs (Wang et al.,
2011), induce the expression of several pro-inflammatory mediators (El-Hage et al., 2006), up-regulate the expression of HIV-1 co-receptors (Steele et al., 2003),
disrupt gut homeostasis by modulating gastrointestinal motility and suppressing intestinal immune functions leading to enhanced gut bacterial translocation and
disease progression during HIV infection (Meng et al., 2015).
macrophages to HIV infection most likely through alteration
of β-chemokines and CCR5 receptor expression (Li et al.,
2003a). Morphine promotes growth of HIV-1 in human
peripheral blood mononuclear cells by altering the function
of human T lymphocytes and monocytes (Peterson et al.,
1990). Furthermore, HIV-1 gp120 primes lymphocytes for
morphine-mediated apoptosis (Moorman et al., 2009).
While the opioid system can act as a cofactor in the
pathogenesis of HIV, in some instances it can also inhibit
HIV expression. Chao et al. reported that activation of KORs
suppresses HIV-1 expression in infected microglial (Chao et al.,
1996) and in human brain cells by potentiation of TNF-α (Chao
et al., 1998). Activation of KORs inhibits expression of HIV-
1 in infected CD4 lymphocyte cultures (Peterson et al., 2001)
and reduces HIV-1 entry through inhibition of envelope gp-
mediated membrane fusion and CXCR4 expression (Lokensgard
et al., 2002). Sharp et al. have shown that activation of DORs
in T cells reduces the expression of HIV-1. Activation of DORs
affects intracellular signaling that is known to mediate CD4 T
cell activation and expression of HIV-1 (Sharp et al., 1998). DOR
activation also attenuates Tat-induced intracellular oxidative
stress in SK-N-SH cells (Wallace et al., 2006). Strazza et al. stated
that MOR activation by DAMGO alters expression of CXCR4
and reduces HIV-1 replication in TF-1 human bone marrow
progenitor cells (Strazza et al., 2014). Furthermore, opioids
suppress IL-16-induced signaling pathways, which in turn inhibit
HIV-1 expression in chronically infected promonocyte clone 1
(Chao et al., 1995).
The effect of opioids on epigenetics, especially miRNA
expression, could affect HIV replication and pathogenesis. For
example, the opioid system inhibits expression of anti-HIV
miRNAs (e.g., miRNA-28, 125b, 150, and 382) that target 3′-UTR
of HIV transcripts (Wang et al., 2011). Interestingly, Purohit
et al. found that down-regulation or inhibition of the activity of
this miRNA can stimulate replication of latent HIV-1 in resting
CD4+ T cells and monocytes (Purohit et al., 2012). Opioids
also reactivate latent HIV infections in vitro which is associated
with activation of reactive oxygen species (ROS) and nuclear
factor-kappa B (NF-κB) (Prottengeier et al., 2014).
Differential expression of alternatively-spliced opioid receptor
isoforms and polymorphisms in HIV-infected subjects could
affect the pathophysiology of HIV infection (Dever et al.,
2014). Proudnikov et al. showed that OPRM1 polymorphism
alters the severity of HIV infection before and after HAART
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(Proudnikov et al., 2012). They also revealed that OPRK1 and
PDYN polymorphism alters the severity of HIV infection and
response to treatment (Proudnikov et al., 2013).
Morphine increases neurotoxic effects of HIV, and also
limits the ability of neurons to recover from sublethal damage
(Masvekar et al., 2014). Also, morphine synergizes the toxic
effect of HIV proteins. For example morphine exacerbates
neuropathogenesis of HIV-1 glycoprotein (gp) 120 by altering
the chemokine balance in the brain (Mahajan et al., 2005).
Importantly, HIV-1 gp120 and morphine cooperatively induce
oxidative stress and affect cell cycle machinery, which may cause
disease progression (Samikkannu et al., 2015). The interaction
of the HIV-1 transactivator of transcription (Tat) and morphine
increases the neurodegenerative effects through MORs signaling
(Zou et al., 2011).
Turchan-Cholewo et al. showed that Tat and morphine
synergistically increase the production of ROS (Turchan-
Cholewo et al., 2009). HIV-Tat triggers opioid signaling in
the microglia through induction of receptor expression or
alters ligand-induced trafficking of opioid receptors (Turchan-
Cholewo et al., 2008). Therapeutic interventions that target the
opioid system could be targeted to mitigate neuropathogenesis
and neuroAIDS. For example, Sagar et al. demonstrated that
using a novel therapeutic approach (neurotargeting via magnetic
nanocarrier) could be effective in targeting opiate-induced
neuropathogenesis and neuroAIDS (Sagar et al., 2015). Yuan
et al. suggested that a properly designed bivalent ligand targeting
the putative MOR and CCR5 heterodimers could block HIV
invasion into host cells by specifically targeting the putative
MOR-CCR5 heterodimer (Yuan et al., 2013).
The data indicates that opioid systems have a significant
effect on HIV infection, pathogenesis, and immune regulation.
Mechanisms associated with enhancement of HIV pathogenesis
through the opioid system appear to work through activation
of opioid receptors and their downstream signaling pathways to
make them possible targets for therapeutic intervention in HIV
infection.
Hepatitis C Virus
The hepatitis C virus (HCV) causes severe liver disorders
such as fibrosis, cirrhosis, and cancer (Webster et al., 2015).
HCV prevalence is high among opioid-dependent individuals
(range 10–90% in different region; UNODC, 2015), and HCV-
related disorders are common causes of morbidity and mortality
in opioid users (Gibson et al., 2011; Nelson et al., 2011).
Opioid users are exposed to needle sharing, unsafe disposal
and unsuitable cleaning of needles, as well as unsafe sex,
which make them prone to HCV infection (Hagan et al.,
2001). Maintenance of opioid agonist therapy (methadone or
buprenorphine) in opioid users is associated with lower incidence
of HCV, which may be an important strategy for prevention
of the spread of HCV among drug users (Tsui et al., 2014).
Furthermore, simultaneous targeting of HCV infection and
opioid dependence has been shown to be effective for drug
users infected with HCV (Murphy et al., 2014). Despite the
high prevalence of HCV in opioid users, little is known about
molecular mechanisms contributing to HCV infection among
opioid-dependent individuals.
Chronic opioid abuse has a severe negative impact on the
immune system (Figure 4). The negative impact of opioids on
host immunity in an important factor in the development of
acute and chronic HCV infections (Zhang et al., 2006). In
vitro investigations indicate that opioids facilitate HCV infection
in hepatocytes by suppressing interferon (IFN)-α-mediated
intracellular innate immunity (Li et al., 2003b, 2007; Wang C.-Q.
et al., 2005). Li et al. demonstrated that morphine compromised
the anti-HCV effect of recombinant IFN-α augmenting HCV
replicon expression in hepatic cells (Li et al., 2003b). They
revealed that morphine inhibited intracellular IFN-α expression
in newly-infectious infected cells, which further facilitates HCV
persistence in human hepatocytes (Li et al., 2007). Wang et al.
reported that morphine withdrawal, a recurrent event during the
course of opioid abuse, inhibits expression of endogenous IFN-
α and enhances HCV replicon expression in hepatic cells (Wang
C.-Q. et al., 2005). Morphine inhibits IFN-α by direct interaction
with IFN-α promoter and interferon regulatory factors (IRF)-5,
IRF-7, and p38 (Li et al., 2003b, 2007; Wang C.-Q. et al.,
2005). These important in vitro findings were confirmed by Ye
et al., who demonstrated that administration of opioids results in
impairment of CD56+ T cell-mediated innate immune function
(secretion of IFN-γ) through up-regulation of cytokine signaling
3 and protein inhibition of activated STAT 3 (SOCS-3), which
may contribute to HCV infection and persistence in the liver (Ye
et al., 2010).
Opioid-induced oxidative damage has been assumed to
contribute to many of the systemic signs of liver disorder
and toxicity as illustrated in mice as well as opioid abusers
(Tennant and Moll, 1995; Payabvash et al., 2006). El-Hage et al.
have shown that morphine accelerates HCV-mediated pathology
by dysregulation of HCV-induced hepatic pro-inflammatory
cytokines expression such as TNF-α and CCL5 and free radical
production such as ROS and nitric oxide (NO) in HCV JFH1-
infected hepatocytes (El-Hage et al., 2011). Furthermore, opioid
system synergizes with the effect of alcohol to accelerate HCV
replication, because enhancement of the effect of alcohol onHCV
replicon expression was abrogated following administration of
naltrexone as an opioid receptor antagonist (Zhang et al., 2003).
Endogenous opioids, like exogenous opioids, act as cofactors
inHCV replication and pathogenesis. For example, β-endorphins
down-modulate T cell anti-bacterial response in HCV patients
by activation of opioid receptors in immune cells (Amati et al.,
2001). The met-enkephalin concentration is high in the liver of
HCV patients and is a useful marker of hepatocellular damage
in chronic HCV (Ciesla et al., 2006). Met-enkephalin activates
MORs and DORs which enhance replication of HCV in hepatic
cells (Bergasa and Boyella, 2008), particularly in the liver of
HCV patients (Boyella et al., 2008), and also interferes with
the anti-viral effect of type I interferon (Floreani et al., 2012).
The low efficiency of interferon therapy for HCV treatment
in some patients could be explained by the effects of hepatic
met-enkephalins (Bergasa and Boyella, 2008; Boyella et al., 2008).
Taken together, these results suggest that opioids accelerate
HCV pathogenesis and establish chronic HCV infection,
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FIGURE 4 | Opioid systems effects on HCV replication and pathogenesis. Opioid systems accelerate HCV pathogenesis and enhance susceptibility to HCV
infection via several mechanisms. Opioid system impair the expression of IFN-α (Li et al., 2007), and IFN-γ (Ye et al., 2010), and also down-regulate the T cell
anti-bacterial response in HCV patients by activation of opioid receptors in immune cells, which accelerates disease progression (Amati et al., 2001). Opioids also
induce the expression of ROS and NO leading to disease progression (El-Hage et al., 2011).
especially in drug abusers. Further consideration should be
given to opioid abuse as a contributing factor for the increase
in HCV infection among opioid-dependent individuals. Better
understanding of the relationship between HCV and the opioid
system may yield new therapeutic intervention in HCV carriers.
Influenza Virus
Opioid systems effect infections caused by HIV and HCV,
but little is known about the role of opioid systems in the
pathogenesis of other clinically important viral pathogens.
Evaluating the effects of the opioid system on influenza infection
could provide valuable information as it is a serious public health.
Influenza causes viral respiratory tract diseases ranging from
mild upper respiratory infection to severe pneumonia (Short
et al., 2014). When airway epithelial cells are infected by the
influenza virus, infiltration of various immune cells occurs. It is
known that infiltrating immune cells are directed against infected
epithelial cells, causing immunopathogenesis (Tahamtan et al.,
2016).
Because opioids alter immune function, it is likely that
this system also effects the immunopathogenesis of influenza
in the pulmonary tract (Figure 5). Coussons-Read et al.
examined the effect of morphine treatment on pulmonary
inflammatory response to intranasal influenza infection in Lewis
rats (Coussons-Read et al., 1999). They show that morphine
impairs the inflammatory response to influenza infection in
the lung by prevention of inflammatory cells in the lung,
lowering the percentage of polymorphonuclear cells in the
bronchoalveolar lavage fluid (BALF), decreasing the protein and
lactate dehydrogenase content in BALF, and reducing the wet
weight of the lung (Coussons-Read et al., 1999). They also
revealed that the influenza virus cleared slowly from the lungs
of morphine-treated rats compared to non-treated and placebo
controls, suggesting that there may be a relationship between
impaired inflammatory response and viral clearance (Coussons-
Read et al., 1998).
Tseng et al. revealed that opioid systems activate MORs
which modulate NK cell cytotoxicity during influenza infection
(Tseng et al., 2005). Importantly, opioids could increase the
risk of pneumonia after influenza as a consequence of immune
suppression function (Dublin et al., 2011). Chen et al. showed
that exposure to methadone significantly increased H1N1 viral
replication in lungs, which might increase the augmented risk
of serious influenza A virus infection in people who receive
opioid-dependence therapy (Chen et al., 2015).
These results suggest that the opioid systems impair or
modulate immune responses induced by the influenza virus that
might be beneficial for controlling viral immunopathogenesis,
but may lead to delayed viral clearance. Although the data clearly
show that opioid system alters the pulmonary inflammatory
response to influenza infection, the mechanism of these effects
remains unclear. An important step in understanding the role
opioids play in pulmonary immune status is unraveling the
underlying mechanism of the effects of opioid system on
pulmonary inflammation.
Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) causes severe respiratory
disease and even death in neonates and the elderly (Lozano
et al., 2012; Salimi et al., 2016). RSV infections such as influenza
causes infiltration of immune cells by infected epithelial cells,
which causes immunopathology (Stoppelenburg et al., 2013).
Opioids are frequently used during mechanical ventilation of
severe RSV infection and some studies have examined the
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FIGURE 5 | Opioid systems effects on influenza/RSV immunopathogenesis. Opioids may attenuate immunopathogenesis of influenza and RSV via
immunomodulatory and anti-inflammatory actions.
effects of opioids and their receptors on RSV infection. A
human study and an experimental model by the authors recently
demonstrated opioid system control of RSV replication in the
lung and of virus-induced pathology (Figure 5). In the human
study, A118G single nucleotide polymorphism rs1799971 in the
OPRM1 gene was found to be associated with RSV disease
severity. Cases with G alleles are less prone to develop severe RSV
infection than those with A alleles (Salimi et al., 2013). A single
nucleotide polymorphism at position 118 in the coding region
of the OPRM1 alters immune response and prevents secretion
of pro-inflammatory cytokines such as IL-6, IL-8, and TNF-α
(Matsunaga et al., 2009). In mice, administration of the opioid
receptor antagonist nalmefene increased RSV viral load and is
associated with increased levels of cytokines and chemokines
in the BALF, enhanced bronchoalveolar cellular influx, and
exaggerated lung pathology. It was also demonstrated that
activation of opioid receptors using µ (DAMGO), κ (U50488),
and δ (DPDPE) agonists reduced neutrophil influx (Salimi et al.,
2013).
Taken together, these results suggested that opioid systems
have a beneficial role in the outcome of respiratory viral
disease and could serve as effective therapeutic targets. Opioid
receptor activation could offer powerful novel pharmacologic
targets to amend RSV-induced immunopathogenesis, although
the clinical effects of pharmaceutical agonists should be
evaluated.
Herpes Simplex Virus
Herpes simplex viruses (HSVs) are a worldwide infectious
agents causing variety of diseases such as oral and genital
lesions, encephalitis, neonatal infections, and tumors (Whitley
and Roizman, 2001). Opioids administration is known to affect
the course of HSV infection because of their immunosuppressive
function. For example, morphine, a broadly studied and widely
used opioid, is known to alter HSV infection, immune response,
as well as latency (Jamali et al., 2007a, 2012; Mojadadi et al., 2009;
Bauchat, 2010).
It has been clearly demonstrated that morphine alters
innate immune responses, which affect the ability of an
infected host to mount a specific immune response and
clear HSV-1 (Sheridan and Moynihan, 2005). Acute morphine
administration diminishes the ability of white blood cells to
induce a protective innate immune defense against HSV-1
infection through inhibition of IFN-γ production and NK
cell activity (Jamali et al., 2007a). Mojadadi et al. found that
acute morphine administration significantly reduced cytolytic
T lymphocyte response, lymphocyte proliferation, and IFN-γ
production, which consequently reactivated HSV-1 latency in
BALB/c mice (Mojadadi et al., 2009). Cellular immune response
plays an important role in the inhibition of HSV reactivation and
withdrawal from morphine has been shown to reduce protective
immunity against acute HSV-1 (Jamali et al., 2012). Endogenous
opioids suppress protective immunity against primary HSV-
1 infection (Jamali et al., 2007b). Paradoxically, morphine
treatment reduced HSV-1-mediated pathology in infected mice
by alleviating some of the unwarranted immunopathological
manifestations associated with these infections, but not by
reducing the viral replication rate (Alonzo and Carr, 1999;Weeks
et al., 2001).
Given the immunosuppressive effects of opioids, it has been
demonstrated that morphine reactivates latent HSV (Davies
et al., 2005). Gieraerts et al. reported high prevalence of HSV
infection in patients receiving epidural morphine following
cesarean section (Gieraerts et al., 1987). A significant association
between the use of epidural morphine which is commonly used
for postoperative analgesia after cesarean section and reactivation
of oral herpes in the obstetric population has also been reported
(Crone et al., 1990).
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Acute morphine administration potentiates the development
of encephalitis in HSV-1 infected mice (Lioy et al., 2006).
In this regard morphine exposure decreases integrity of the
blood-brain barrier (BBB) and might explain its potential role
for involvement of BBB in the development of encephalitis in
morphine-treated mice (Lioy et al., 2006). It has been shown
that a hippocampal dynorphin system causes seizures in HSV-1
infected rats. Dynorphin is the preferred endogenous opioid for
KOR activation with broad homeostatic functions (Solbrig et al.,
2006). Furthermore, activation of peripheral MORs by morphine
and loperamide suppresses mechanical allodynia in mice with
herpetic pain (Sasaki et al., 2007, 2008).
Altogether, these findings indicate that opioid systems
suppress protective immunity against HSV infection and induce
HSV reactivation. More extensive studies are required to explore
the role of opioid system in HSV and other herpes viruses
such as EBV and CMV infection for more efficient therapeutic
approaches.
CONCLUSION
In recent years, data the opioid system has received attention
because it demonstrates the influence on immune cells and
immune function. In addition, there is a large body of evidence
from in vivo and in vitro models indicating that opioid systems
effect viral replication and virus-mediated pathology. The diverse
effects of the opioid system on viral infection imply involvement
of different mechanisms. The effect of opioids on immune
cells, epigenetics, viral, and cellular factors are implicated in
the pathogenesis. For the majority of viruses, opioid system
enhances viral pathogenesis by modulation of immune responses
(Sheridan and Moynihan, 2005; Wang X. et al., 2005; Zhang
et al., 2006). Accordingly, blockage of opioid receptors can
potentially be applied for viral control. On the other hand,
activation of opioid receptors is beneficial for controlling viral
pathogenesis in those viral infections where host immune
responses are pathogenic (Coussons-Read et al., 1999; Salimi
et al., 2013).
Exploring the interplay between viruses and opioid system
and corresponding molecular mechanisms is an important tool
for understanding the effect of opioids, mechanisms of action,
and development of therapeutic strategies. Clearly more work
needs to be done, especially in clinical settings, to promote
the importance of understanding the exact interaction between
opioid system and viral infections. Because endogenous opioid
systems have favorable functions, manipulation of these systems
should be performedwith caution. To investigate this interaction,
further research is required in the following areas:
• While opioids and their receptors are involved in the
pathogenesis of several viral infections, the exact mechanisms
remain unknown. For example, the signaling pathways
between opioids and viruses require further investigation.
• Although the in vitro and animal model effects of opioids
are well documented, few have explored the effect of opioids
on viral infection in clinical settings and future studies with
a larger sample sizes are necessary to determine the opioid
system effects.
• Initial data indicates a beneficial role of opioids in the
outcome of respiratory viral diseases. Novel essential
therapeutic approaches based on opioid system activation
and/or inhibition are required for full characterization.
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